Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-25T19:23:50.724Z Has data issue: false hasContentIssue false

25 - Pharmacological treatments for schizophrenia

from Part III - Specific treatments

Published online by Cambridge University Press:  12 May 2010

Stephen R. Marder
Affiliation:
West Los Angeles VA Healthcare Center Los Angeles, CA USA
Peter B. Jones
Affiliation:
Department of Psychiatry Addenbrooke's Hospital Cambridge UK
Peter Tyrer
Affiliation:
Imperial College of Science, Technology and Medicine, London
Kenneth R. Silk
Affiliation:
University of Michigan, Ann Arbor
Get access

Summary

Editor's note

It is interesting that the most researched and possibly most important area of therapeutics in mental illness, the drug treatment of schizophrenia, is covered in less than 4000 words in this chapter. Why is this? Is it that our two authors are so good at précis that they can summarize in 10 words information that would use 100 words in the writing of others, or is it because the information is so diffuse that no conclusions can be drawn? Or is there another reason: that the subject has such a strong evidence base that it is possible to describe it both briefly and fully? Perhaps the last option has it. Lord Moran of Manton, perhaps best known as the personal doctor of Winston Churchill, in his Harveian oration of 1945 put it this way:-

“The physician who knows what is wrong with a patient and has an effective remedy can cut the cackle. He has no need of it”. Now we are not suggesting that the other longer chapters are full of cackle, but when there is more doubt, there is more conjecture and this takes up more space. As Adams et al. (2006) states, ‘the literature on the drug treatment of schizophrenia is actually quite clear and unequivocal; the problem is that in rich countries with powerful drug companies, the constant jockeying for market position tends to confuse by setting up winners and losers on flimsy evidence.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adams, C., Tharyan, P., Coutinho, E. S.et al. (2006). The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. British Journal of Psychiatry, 189, 391–2.CrossRefGoogle ScholarPubMed
American Diabetes Association Guidelines (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.CrossRef
Anthony, W. A., Rogers, E. S., Cohen, M. & Davies, R. R. (1995). Relationships between psychiatric symptomatology, work skills, and future vocational performance. Psychiatric Services, 46, 353–8.Google ScholarPubMed
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D. & Sheitman, B. (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry, 158, 518–26.CrossRefGoogle ScholarPubMed
Davis, J. M. (1975). Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry, 132, 1237–45.Google ScholarPubMed
Davis, J., Barter, J. & Kane, J. M. (1989). Antipsychotic drugs. In Comprehensive Textbook of Psychiatry V, ed. Kaplan, H. I. & Sadock, B. J., pp. 1591–1626. Baltimore, Williams and Wilkins.Google Scholar
Davis, J. M., Chen, N. & Glick, I. D. (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry, 60, 553–64.CrossRefGoogle ScholarPubMed
Geddes, J., Freemantle, N., Harrison, P. & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal, 321, 1371–6.CrossRefGoogle ScholarPubMed
Hogarty, G. E., Ulrich, R. F., Mussare, F. & Aristigueta, N. (1976). Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Diseases of the Nervous System, 37, 494–500.Google ScholarPubMed
Honer, W. G., Thornton, A. E., Chen, E. Y.et al. (2006). Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New England Journal of Medicine, 354, 472–82.CrossRefGoogle ScholarPubMed
Josiassen, R. C., Joseph, A., Kohegyi, E.et al. (2005). Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry, 162, 130–6.CrossRefGoogle ScholarPubMed
Jones, P. B., Barnes, T. R., Davies, L.et al. (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry, 63, 1079–87.CrossRefGoogle Scholar
Kane, J. M., Honigfeld, G., Singer, J., Meltzer, H. & Group tCCS. (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Archives of General Psychiatry, 45 789–96.CrossRefGoogle Scholar
Keck, P. E. Jr, McElroy, S. L. & Strakowski, S. M. (1999). Schizoaffective disorder: role of atypical antipsychotics. Schizophrenia Research, 35 (Suppl. 2), S5–S12.CrossRefGoogle ScholarPubMed
Lehman, A. F., Lieberman, J. A., Dixon, L. B.et al. (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 161(Suppl. 2), 1–56.Google ScholarPubMed
Leucht, S., Pitschel-Walz, G., Abraham, D. & Kissling, W. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51–68.CrossRefGoogle ScholarPubMed
Leucht, S., Barnes, T. R., Kissling, W., Engel, R. R., Correll, C. & Kane, J. M. (2003). Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry, 160, 1209–22.CrossRefGoogle ScholarPubMed
Levinson, D. F., Umapathy, C. & Musthaq, M. (1999). Treatment of schizoaffective disorder and schizophrenia with mood symptoms. American Journal of Psychiatry, 156, 1138–48.Google ScholarPubMed
Lewis, S. W., Barnes, T. R., Davies, L.et al. (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin, 32, 715–23.CrossRefGoogle ScholarPubMed
Lieberman, J. A., Phillips, M., G u, H.et al. (2003a). Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology, 28, 995–1003.CrossRefGoogle Scholar
Lieberman, J. A., Tollefson, G., Tohen, M.et al. (2003b). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry, 160, 1396–404.CrossRefGoogle Scholar
Lieberman, J. A., Stroup, T. S., McEvoy, J. P.et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–23.CrossRefGoogle ScholarPubMed
Marder, S. R. (1999). An approach to treatment resistance in schizophrenia. British Journal of Psychiatry (Suppl. 37), 19–22.Google Scholar
Marder, S. R., Essock, S. M., Miller, A. L.et al. (2002). The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia Bulletin, 28, 5–16.CrossRefGoogle Scholar
Marder, S. R., Essock, S. M., Miller, A. L.et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 1334–49.CrossRefGoogle ScholarPubMed
McEvoy, J. P., Lieberman, J. A., Stroup, T. S.et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry, 163, 600–10.CrossRefGoogle Scholar
Miller, A. L., Hall, C. S., Buchanan, R. W.et al. (2004). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry, 65, 500–8.CrossRefGoogle ScholarPubMed
O'Donnell, C., Donohoe, G., Sharkey, L.et al. (2003). Compliance therapy: a randomised controlled trial in schizophrenia. British Medical Journal, 327, 834.CrossRefGoogle Scholar
Resnick, S. G., Rosenheck, R. A. & Lehman, A. F.An exploratory analysis of correlates of recovery. Psychiatric Services, 55, 540–7.CrossRef
Stroup, T. S., Lieberman, J. A., McEvoy, J. P.et al. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry, 163, 611–22.CrossRefGoogle ScholarPubMed
Putten, T. (1975). The many faces of akathisia. Comparative Psychiatry, 16, 43–7.CrossRefGoogle ScholarPubMed
Yagcioglu, A. E., Kivircik, A., Turgut, T. I.et al. (2005). A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry, 66, 63–72.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×